MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Search

Actinium Pharmaceuticals Inc

Avatud

1.61 2.55

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.56

Max

1.62

Põhinäitajad

By Trading Economics

Sissetulek

9.1M

-6.9M

Kasumimarginaal

-821.235

Töötajad

27

EBITDA

9.1M

-7.5M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+181.25% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

12. nov 2025

Turustatistika

By TradingEconomics

Turukapital

-1.2M

51M

Eelmine avamishind

-0.94

Eelmine sulgemishind

1.61

Actinium Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. okt 2025, 23:30 UTC

Kuumad aktsiad

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2. okt 2025, 21:21 UTC

Tulu

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3. okt 2025, 00:00 UTC

Omandamised, ülevõtmised, äriostud

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2. okt 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2. okt 2025, 23:39 UTC

Market Talk

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2. okt 2025, 23:29 UTC

Omandamised, ülevõtmised, äriostud

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2. okt 2025, 23:29 UTC

Omandamised, ülevõtmised, äriostud

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2. okt 2025, 23:29 UTC

Omandamised, ülevõtmised, äriostud

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2. okt 2025, 23:00 UTC

Market Talk

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2. okt 2025, 22:54 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Scales's JV Buyout Lauded by Bull -- Market Talk

2. okt 2025, 22:54 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Global Forex and Fixed Income Roundup: Market Talk

2. okt 2025, 22:46 UTC

Market Talk

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2. okt 2025, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2. okt 2025, 21:17 UTC

Omandamised, ülevõtmised, äriostud

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2. okt 2025, 20:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Energy & Utilities Roundup: Market Talk

2. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. okt 2025, 20:49 UTC

Omandamised, ülevõtmised, äriostud

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2. okt 2025, 20:00 UTC

Omandamised, ülevõtmised, äriostud

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2. okt 2025, 19:20 UTC

Market Talk

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2. okt 2025, 19:10 UTC

Market Talk

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2. okt 2025, 19:04 UTC

Market Talk

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2. okt 2025, 18:46 UTC

Omandamised, ülevõtmised, äriostud

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2. okt 2025, 18:46 UTC

Omandamised, ülevõtmised, äriostud

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2. okt 2025, 18:46 UTC

Omandamised, ülevõtmised, äriostud

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2. okt 2025, 18:45 UTC

Omandamised, ülevõtmised, äriostud

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2. okt 2025, 18:45 UTC

Omandamised, ülevõtmised, äriostud

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2. okt 2025, 18:44 UTC

Omandamised, ülevõtmised, äriostud

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2. okt 2025, 18:44 UTC

Omandamised, ülevõtmised, äriostud

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2. okt 2025, 18:44 UTC

Omandamised, ülevõtmised, äriostud

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2. okt 2025, 18:43 UTC

Omandamised, ülevõtmised, äriostud

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Võrdlus sarnastega

Hinnamuutus

Actinium Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

181.25% tõus

12 kuu keskmine prognoos

Keskmine 4.5 USD  181.25%

Kõrge 5 USD

Madal 4 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Actinium Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

2

Osta

0

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.
help-icon Live chat